AHA/ASA Guideline

Guideline for the Management of Patients with Unruptured Intracranial Aneurysms

A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association

The American Academy of Neurology (AAN) affirms the value of this guideline as an educational tool for neurologists

Endorsed by the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS)

Endorsed by the Society of NeuroInterventional Surgery (SNIS)
B. Gregory Thompson, MD, Chair; Robert D. Brown Jr., MD, MPH, FAHA, Co-Chair; Sepideh Amin-Hanjani, MD, FAHA; Joseph P. Broderick, MD, FAHA; Kevin M. Cockcroft, MD, MSc, FAHA; E. Sander Connolly, Jr., MD, FAHA; Gary R. Duckwiler, MD, FAHA; Catherine C. Harris, PhD, RN; Virginia J. Howard, PhD, MSPH, FAHA; S. Claiborne (Clay) Johnston, MD, PhD; Philip M. Meyers, MD, FAHA; Andrew Molyneuz, MD; Christopher S. Ogilvy, MD; Andrew J. Ringer, MD; James Torner, PhD, MS, FAHA on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention.
Michael T. Mullen, MD MS
Assistant Professor
Department of Neurology
Perelman School of Medicine,
University of Pennsylvania
### Applying classification of recommendations and levels of evidence

#### Size of Treatment Effect

- **Class I**
  - Benefit >> Risk
  - Procedure/Treatment SHOULD be performed/administered

- **Class IIa**
  - Benefit >> Risk
  - Additional studies with focused objectives needed
  - IT IS REASONABLE to perform procedure/administer treatment

- **Class IIb**
  - Benefit > Risk
  - Additional studies with broad objectives needed; additional registry data would be helpful
  - Procedure/Treatment MAY BE CONSIDERED

- **Class III**
  - No Benefit or Class III Harm
    - Procedure/Text
    - Treatment
    - COR III: No Benefit
      - Helpful
      - Not Proven Benefit
    - COR III: Harm
      - Excess Cost w/o Benefit or Harmful
      - Harmful to Patients

#### Estimate of Certainty (Precision) of Treatment Effect

- **Level A**
  - Multiple populations evaluated*
  - Data derived from multiple randomized clinical trials or meta-analyses
  - Recommendation that procedure or treatment is useful/effective
  - Sufficient evidence from multiple randomized trials or meta-analyses

- **Level B**
  - Limited populations evaluated*
  - Data derived from a single randomized trial or nonrandomized studies
  - Recommendation that procedure or treatment is useful/effective
  - Evidence from single randomized trial or nonrandomized studies

- **Level C**
  - Very limited populations evaluated
  - Only consensus opinion of experts, case studies, or standard of care
  - Recommendation that procedure or treatment is useful/effective
  - Only diverging expert opinion, case studies, or standard of care

#### Suggested Phrases for Writing Recommendations

- **Class I**
  - Should be recommended
  - Is indicated
  - Is useful/effective/beneficial

- **Class IIa**
  - May/might be considered
  - Is probably recommended or indicated
  - Can be useful/effective/beneficial

- **Class IIb**
  - May/might be considered
  - Is probably recommended or indicated
  - Is useful/effective/beneficial

- **Class III**
  - Not recommended
  - Is not indicated
  - Should not be performed/administered/other

#### Comparative Effectiveness Phrases*

- Treatment/strategy A is recommended/administered in preference to treatment B
- Treatment A should be chosen over treatment B
- Treatment/strategy A is probably recommended/administered in preference to treatment B
- It is reasonable to choose treatment A over treatment B

---

*American Heart Association | American Stroke Association*
I. Introduction
II. Risk factors for aneurysm development, growth and rupture
III. Clinical presentation
IV. Diagnosis/imaging
V. Screening in asymptomatic individuals
VI. Natural history of unruptured aneurysms
VII. Surgical Clipping of unruptured aneurysms
VIII. Endovascular treatment of unruptured aneurysms
IX. Comparative efficacy of clipping vs. coiling
X. Aneurysm follow-up
XI. Conclusion
I. Introduction

Incidentally discovered 6mm unruptured aneurysm arising from an MCA branch
I. Introduction

• Unruptured intracranial aneurysms (UIA) are common, occurring in approximately 3.2% of the general population.

• They are often discovered incidentally on cerebrovascular imaging.

• The **VAST** majority of UIA will not rupture.
I. Introduction

It is estimated that out of 1 million adults in the general population with mean age of 50:

- **32,000** will harbor an UIA
- Only **80 (0.25%)** would be expected to present with subarachnoid hemorrhage (SAH).
I. Introduction

• Despite the low risk of rupture, aneurysmal SAH is potentially catastrophic, due to high rates of morbidity and mortality.

• As a result, patients and physicians are often faced with the dilemma of whether to treat patients with UIA or manage them conservatively.

• The purpose of this statement is to provide guidance for healthcare providers and to serve as a framework for decision making when a UIA is discovered.
II. Risk Factors for Aneurysm Development, Growth, and Rupture

Non-modifiable Risk Factors for Aneurysm Development

- Older age
- Female sex
- Family history of aneurysms/SAH
- At risk disorders (<10% of UIA):
  - Polycystic Kidney Disease, Type IV Ehlers Danlos, Marfan’s Syndrome, Coarctation of the aorta, Bicuspid aortic valve, and Fibromuscular dysplasia, Microcephalic osteodysplastic primordial dwarfism, and intracranial arteriovenous malformation among others.
II. Risk Factors for Aneurysm Development, Growth, and Rupture

Modifiable Risk Factors for Aneurysm Development:

- Smoking
- Hypertension
II. Risk Factors for Aneurysm Development, Growth, and Rupture

Potential Risk Factors for Aneurysm Growth

- *Not well studied*
- May include:
  - Female sex
  - Smoking
  - Hypertension
  - Excessive alcohol
  - Larger aneurysm size
  - Arterial branch related aneurysm
Risk Factors for Aneurysm Rupture:

• Aneurysm size
  – Larger aneurysm = Increased Risk

• Aneurysm location
  – Anterior communicating artery and pericallosal may be over-represented in the ruptured cohort

• Other potential risk factors (less well defined):
  – Aneurysm morphology, aneurysm growth, smoking, hypertension, prior SAH, and family history of SAH.
## II. Risk Factors for Aneurysm Development, Growth, and Rupture

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Given that smoking appears to increase risk of UIA formation, patients with UIA should be counseled regarding the importance of smoking cessation.</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Given that hypertension may play a role in growth and rupture of intracranial aneurysms, patients with UIA should monitor blood pressure and undergo treatment for hypertension.</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Aneurysmal growth may increase the risk of rupture and intermittent imaging studies to follow those UIAs managed conservatively should be considered.</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
III. Clinical Presentation

UIA often identified:

- After SAH from another aneurysm
- Incidentally during evaluation of unrelated neurologic symptoms
- Symptomatic from mass effect causing cranial nerve palsy
  - May increase risk of rupture up to 4x
  - Sudden onset of CN III palsy may indicate expansion and imminent risk of rupture
III. Clinical Presentation

Right Posterior Communicating Artery Aneurysm

- Presented with a 3rd Nerve Palsy from compression
- Suggests high risk of rupture
- Urgent treatment is indicated
### III. Clinical Presentation

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with an aneurysmal SAH should undergo careful assessment for a coexistent unruptured intracranial aneurysm</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Early treatment is generally indicated for patients presenting with cranial nerve palsy caused by an UIA</td>
<td>Class I, LOE C</td>
</tr>
</tbody>
</table>
### III. Clinical Presentation

<table>
<thead>
<tr>
<th>Class II recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The effectiveness of the routine treatment of unruptured intracranial aneurysms for the prevention of ischemic cerebrovascular disease is uncertain.</td>
<td>Class IIb, LOE C</td>
</tr>
</tbody>
</table>
Digital Subtraction Angiography
- Gold standard for aneurysm diagnosis
- Low risk of contrast and radiation exposure, cerebral infarction, aneurysmal rupture, arterial injury
  - Permanent neurologic complication rate of 0.07%

CT Angiography
- High sensitivity and specificity, especially for aneurysms >3mm
- May not fully delineate details of vascular anatomy required for treatment decisions
- Risk of contrast and radiation exposure

MR Angiography
- High sensitivity, especially for aneurysms >3mm
- Can be done without contrast or radiation
Follow-up imaging:

• Untreated aneurysms should be followed intermittently

• Follow-up requirements for treated aneurysms are uncertain
  – Typically not performed if aneurysm is adequately clipped and aneurysm is completely occluded
  – Typically performed 6-12 months after coiling
    ♦ Further imaging depends on occlusion status and results of early follow-up imaging

• MRI is a reasonable option for follow-up of UIA given lack of radiation/contrast.
IV. Diagnosis/Imaging

CT Angiography demonstrates a small UIA

Wide necked 3mm Right ICA Aneurysm on CTA

Courtesy Michael T. Mullen MD – University of Pennsylvania
### IV. Diagnosis/Imaging

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CTA and MRA are useful for detection and follow-up of UIA</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Coiled aneurysms, especially those with wide neck or dome diameters or those that have residual filling should have follow-up evaluation.</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
### IV. Diagnosis/Imaging

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DSA can be useful compared to noninvasive imaging for identification and evaluation of cerebral aneurysms if surgical or endovascular treatment is being considered.</td>
<td>Class IIa, LOE B</td>
</tr>
<tr>
<td>DSA is reasonable as the most sensitive imaging for follow-up of treated aneurysms</td>
<td>Class IIa, LOE C</td>
</tr>
<tr>
<td>It is reasonable to perform MRA as an alternate for follow-up of treated aneurysms with DSA used as necessary when deciding on therapy</td>
<td>Class IIa, LOE C</td>
</tr>
<tr>
<td>The importance of surveillance imaging after endovascular treatment of UIAs lacking high risk features for recurrence remains unclear, but is probably indicated</td>
<td>Class IIa, LOE C</td>
</tr>
</tbody>
</table>
V. Screening

• Routine screening for UIA in the general population is not recommended

• Screening should be considered in high risk patients:
  – 2 or more family members with aneurysm or SAH
  – Family history of intracranial aneurysm and evidence of autosomal dominant polycystic kidney disease

• Screening may be considered in other at-risk populations:
  – Type IV Ehlers-Danlos, microcephalic osteodysplastic primordial dwarfism, coarctation of the aorta, or bicuspid aortic valve
  – Single first degree relative with SAH
### V. Screening

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with two or more family members with intracranial aneurysm or subarachnoid hemorrhage should be offered aneurysmal screening by CT or MR angiography. Risk factors which predict a particularly high risk of aneurysm occurrence in such families include history of hypertension, smoking, and female gender.</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Patients with a history of autosomal dominant polycystic kidney disease, particularly those with a family history of intracranial aneurysm should be offered screening by CT or MR angiography</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
V. Screening

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>It is reasonable to offer CT or MR angiography to patients with coarctation of the aorta and patients with microcephalic osteodysplastic primordial dwarfism.</td>
<td>Class IIa, LOE B</td>
</tr>
</tbody>
</table>
Many studies have suggested that rupture risk is dependent on aneurysm size

Low rates of rupture in UIA <7-10mm

- Meta-analysis of 19 studies and 6556 UIA
  - Annual rupture rate for UIA <7mm was 0.4%
  - Most, 70%, of these subjects came from two international studies (ISUIA)
  - Other data published since then have reported variable rupture rates, from 0% to 1%
VI. Natural History of UIA

• Aneurysm growth has been associated with an increased risk of aneurysm rupture

• History of prior SAH from a different aneurysm may be a risk factor for rupture of UIA at smaller aneurysm sizes

• It may be reasonable to take these factors into account when determining how to manage an UIA.
VI. Natural History of UIA

History of SAH from a different aneurysm may be a risk factor for rupture of other small UIA

Multiple aneurysms arising from the right A1 and the AComm

Courtesy David K Kung MD – University of Pennsylvania
## VI. Natural History of UIA

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aneurysms with documented enlargement during follow-up should be offered treatment</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
### VI. Natural History of UIA

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior history of aneurysmal subarachnoid hemorrhage may be considered to be an independent risk factor for future hemorrhage secondary to a different, small, unruptured aneurysm</td>
<td>Class IIb, LOE B</td>
</tr>
<tr>
<td>Treatment of UIA in patients with a family history of intracranial aneurysm is reasonable even in aneurysms at smaller sizes</td>
<td>Class IIa, LOE B</td>
</tr>
</tbody>
</table>
VII. Surgical Clipping of UIA

• Meta-analysis of 60 studied published between 1990-2011 found that up to 1 year after surgery:
  – Mortality rate of 1.7%
  – Morbidity, defined by lack of independence, was 5%
  – Cognitive dysfunction common
  – 85% of studies were poor quality based on STROBE criteria

• A single large prospective study (ISUIA) of 1917 patients found:
  – Mortality rate 2.3%
  – Morbidity (modified Rankin score>2 and/or impaired cognition) in 12.1%
  – Cerebral infarction in 11%, hemorrhage in 4%
Efficacy and Durability

• Believed to provide definitive and long-term treatment
  – Data confirming this is lacking
  – Limited evidence suggests residual aneurysm/incomplete occlusion in 7-8% of cases.

• Subsequent SAH rates, after clipping, are very low

• Follow-up imaging to confirm occlusion within 5-10 years, or even up to 20 years in younger patients, could be considered
VII. Surgical Clipping of UIA

Risk Factors for Poor Outcome after Clipping

• **Lesion**: aneurysm size > 10mm, posterior circulation location

• **Patient**: age > 50, compressive symptoms, prior ischemic stroke.

• **Surgeon/Hospital**: surgeon inexperience, hospital volume < 20 cases per year
VII. Surgical Clipping of UIA

Left PICA Aneurysm

Clip in Position

Clipping completed

Courtesy David K Kung MD – University of Pennsylvania
## VII. Surgical Clipping of UIA

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient age, family history of cerebral aneurysm rupture and aneurysm location, morphology, size, and documented growth should be taken into account when considering surgical clipping of an UIA.</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Imaging post surgical interventions, to document aneurysm obliteration, is recommended given the differential risk of growth and hemorrhage for completely versus incompletely obliterated aneurysms.</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Surgical treatment of UIA is recommended to be performed at higher volume centers (e.g. performing &gt;20 cases annually).</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
## VII. Surgical Clipping of UIA

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long-term follow-up imaging may be considered after surgical clipping given the combined risk of aneurysm recurrence and de novo aneurysm formation. Long-term follow-up may be particularly important for those aneurysms that are incompletely obliterated during initial treatment.</td>
<td>Class IIb, LOE B</td>
</tr>
<tr>
<td>The use of specialized intraoperative tools and techniques for avoiding vessel compromise or residual aneurysms may be considered to reduce the adverse outcomes with operative management of UIA.</td>
<td>Class IIb, LOE C</td>
</tr>
</tbody>
</table>
• Most reports on the efficacy and safety of endovascular treatment are small and low-quality.
  – Technical failure rates between 0-10%
  – Complication rates between 5-10%

• A large prospective study of 461 patients (ISUIA):
  – Combined morbidity/mortality of 7.1% in patients without prior SAH
  – Combined morbidity/mortality of 9.8% in patients with prior SAH

• Another large prospective study of 649 patients (ATENA):
  – Complete occlusion in 59%
  – Thromboembolic complications in 5.4%, with permanent symptoms in 2.6% and death in 0.9%.
Durability of aneurysm occlusion may be problematic

- Meta-analysis of 71 studies reported aneurysm regrowth or recurrence in 24.4% at up to 3.2 years of follow-up.

- Additional techniques to improve aneurysm occlusion:
  - Coated Coils
    - NOT beneficial.
  - Balloon remodeling and stent-assisted occlusion
    - Unknown benefit
  - Liquid embolic agent (primarily in large or giant aneurysms)
    - Complete occlusion rate of 79%, serious AE in 26.8%
VIII. Endovascular Treatment of UIA

9.4mm para-ophthalmic aneurysm pre-treatment

Post coil-embolization

Courtesy Timothy R. Miller MD – University of Maryland
VIII. Endovascular Treatment of UIA

Stent-assisted coil embolization of a carotid terminus aneurysm

Left ICA Terminus Aneurysm

After stent-assisted coiling

Courtesy David K Kung MD – University of Pennsylvania
# VIII. Endovascular Treatment of UIA

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endovascular treatment of UIAs is recommended to be performed at high volume centers</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>The procedural risk of radiation exposure should be explicitly reviewed in the consent process for endovascular procedures</td>
<td>Class I, LOE C</td>
</tr>
</tbody>
</table>
### VIII. Endovascular Treatment of UIA

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endoluminal flow diversion represents a new treatment strategy that may be considered in carefully selected cases.</td>
<td>Class IIb, LOE B</td>
</tr>
<tr>
<td>Other emerging technologies to treat UIA, such as liquid embolic agents represent new treatment strategies that may be considered in carefully selected cases.</td>
<td>Class IIb, LOE C</td>
</tr>
<tr>
<td>The long-term effects of these newer approaches remain largely unknown. Strict adherence to the indications for use is indicated until additional trial data demonstrates an incremental improvement in safety and efficacy over existing technologies.</td>
<td>Class IIa, LOE C</td>
</tr>
</tbody>
</table>
### VIII. Endovascular Treatment of UIA

<table>
<thead>
<tr>
<th>Class III Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use of coated coils is not beneficial compared to bare metal coils</td>
<td>Class III, LOE A</td>
</tr>
</tbody>
</table>
Compared to clipping, *endovascular therapy has*:

- Reduced morbidity/mortality and shorter length of stay
  - Even greater benefit in patients >60 years
- Lower rates of aneurysm occlusion and higher risk of recurrence
IX. Comparative Efficacy of Clipping vs. Coiling

Special circumstances to consider:

• With current technology, microsurgical repair has an advantage for most middle cerebral artery aneurysms

• Endovascular treatment has an advantage for most basilar apex and vertebro-basilar aneurysms
### IX. Comparative Efficacy of Clipping vs. Coiling

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgical clipping is an effective treatment for UIAs that are considered for treatment</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>Patients with UIAs who are considered for treatment should be fully informed about the</td>
<td>Class I, LOE B</td>
</tr>
<tr>
<td>risks and benefits of both endovascular and microsurgical aneurysm clipping</td>
<td></td>
</tr>
</tbody>
</table>
## IX. Comparative Efficacy of Clipping vs. Coiling

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endovascular coiling is an effective treatment for selected UIAs that are considered for treatment</td>
<td>Class IIa, LOE B</td>
</tr>
<tr>
<td>Endovascular coiling is associated with a reduction in procedural morbidity and mortality over surgical clipping in selected cases but has an overall higher risk of recurrence.</td>
<td>Class IIb, LOE B</td>
</tr>
</tbody>
</table>
X. Aneurysm Follow-up

For patients managed conservatively without clipping or coiling:

- Multiple studies have documented that aneurysms can grow over time
- Aneurysm growth may be a risk factor for hemorrhage
- Routine follow-up imaging may be useful, but no studies have specifically addressed modality or timing of follow-up
X. Aneurysm Follow-up

• Most studies indicate a preference for:
  – First follow-up imaging 6-12 months after initial discovery
  – Every 1-2 years once stability is documented.

• There may come a point in which the risks of intervention would be unacceptably high and follow-up imaging can be discontinued
  – Advanced age
  – Medical comorbidities that increase procedural risk or decrease life expectancy
X. Aneurysm Follow-up

• Both CTA and MRA have been utilized for aneurysm follow-up

• It is unknown if one modality is superior to another

• Because *time of flight MRA* does not require contrast and does not involve x-ray radiation, this may be the most appropriate first line method
X. Aneurysm Follow-up

Time of Flight MRA may be ideal for routine follow-up of UIA because it does not require contrast and there is no radiation exposure.

Courtesy Michael Mullen MD – University of Pennsylvania
### X. Aneurysm Follow-up

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients with unruptured intracranial aneurysms that are managed non-invasively without either surgical or endovascular intervention, radiographic follow-up with magnetic resonance angiography (MRA) or computed tomographic angiography (CTA) at regular intervals is indicated. The optimal interval and duration of recommended follow-up are uncertain.</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
### X. Aneurysm Follow-up

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>For patients with UIA that are managed non-invasively without either surgical or endovascular intervention, a first follow-up study at 6-12 months after initial discovery, followed by subsequent yearly or every other year follow-up may be reasonable.</td>
<td>Class IIb, LOE C</td>
</tr>
<tr>
<td>For patients with UIA that are managed non-invasively and in whom there are no contra-indications to MR imaging, it may be reasonable to consider TOF MRA in favor of CTA for repeated long term follow-up.</td>
<td>Class IIb, LOE C</td>
</tr>
</tbody>
</table>
XI. Conclusion

- UIAs are common. SAH is a feared complication of UIA, but the vast majority of UIAs (>99%) will not rupture.

- Modifiable risk factors for aneurysms are hypertension and cigarette smoking.

- Larger aneurysm size portends a higher risk of rupture.

- Growth of UIA is associated with rupture and could be an indication for repair.
More strongly consider repair of UIA when:
- Prior subarachnoid hemorrhage from a different aneurysm
- Family history of intracranial aneurysms
- Symptoms attributed to the aneurysm, such as cranial nerve compression

Aneurysms managed conservatively should have serial imaging
- Time of flight MRA preferred because it does not require intravenous contrast and does not involve radiation.
When treatment is elected digital subtraction angiography is indicated to:
- Plan repair
- Define whether the aneurysm has been completely occluded post-procedure.

It is uncertain if any populations should undergo routine screening for asymptomatic UIA.
- Two populations to consider:
  - Autosomal dominant polycystic kidney disease
  - Strong family history of aneurysm or subarachnoid hemorrhage.
XI. Conclusion

• The results of UIA treatment appear to be inferior in low volume centers (<20 cases per year)

• Surgical repair is generally associated with:
  – higher rates of aneurysm obliteration
  – lower rates of recurrence
  – higher perioperative morbidity

• Early documentation of the degree of aneurysm obliteration is necessary following any repair to guide the frequency of further follow-up imaging
### XI. Conclusion

<table>
<thead>
<tr>
<th>Class I Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Several factors should be considered in selection of the optimal management of UIA, including the size, location, and other morphological characteristics of the aneurysm, documented growth on serial imaging, the age of the patient, a history of prior aneurysmal subarachnoid hemorrhage, family history of cerebral aneurysm, the presence of multiple aneurysms, or the presence of concurrent pathology such as arteriovenous malformations or other cerebrovascular or inherited pathology that may predispose to a higher risk of hemorrhage.</td>
<td>Class I, LOE C</td>
</tr>
<tr>
<td>Patients with UIA who are considered for treatment should be fully informed about the risks and benefits of both endovascular and microsurgical treatment as alternatives to secure UIAs and prevent bleeding.</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
**XI. Conclusion**

<table>
<thead>
<tr>
<th>Class I Recommendations (Continued)</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The results of UIA treatment are inferior at low volume centers and hence treatment is recommended to be performed at higher volume centers.</td>
<td>Class I, LOE B</td>
</tr>
</tbody>
</table>
### XI. Conclusion

<table>
<thead>
<tr>
<th>Class II Recommendations</th>
<th>Class, Level of Evidence (LOE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data from prospective and retrospective studies from multiple national and international investigations indicate that microsurgical clip ligation may confer more durable protection against aneurysm regrowth, but coil embolization may be superior to surgical clipping with respect to procedural morbidity and mortality, length of stay, and hospital costs, so it may be reasonable to choose endovascular therapy over surgical clipping in the treatment of select UIAs, particularly in cases where surgical morbidity is high, such as the basilar apex and in the elderly.</td>
<td>Class IIb, LOE B</td>
</tr>
<tr>
<td>The treatment risk of patients with UIAs is related to advancing age, medical co-morbidities, and aneurysm location and size, so in older patients (age&gt;65) and those with associated medical morbidities with small asymptomatic UIAs with low hemorrhage risk by location, size, morphology, family history and other relevant factors, observation is a reasonable</td>
<td>Class IIa, LOE B</td>
</tr>
</tbody>
</table>